II. Indications
- Similar indications to standard Insulin Glargine concentration (100 units/ml)
- Promoted as a longer acting Lantus (closer to 24 hour duration) at several fold higher cost
- However, in practice, U-300 likely adds little benefit over standard Insulin Glargine
-
Type 1 Diabetes Mellitus
- Basal insulin for those not using an Insulin Pump (or for emergency use when Insulin Pump fails)
- Type 2 Diabetes Mellitus with Insulin Resistance refractory to non-Insulin therapy
III. Medications
IV. Pharmacokinetics
V. Dosing
- See Insulin Dosing
- See Insulin Dosing in Type I Diabetes
- See Insulin Dosing in Type II Diabetes
- Insulin Glargine U-300 is injected subcutaneously
- Do not adjust Toujeo dose more often than every 3-4 days
- Insulin Naive Starting Dose in Type 2 Diabetes Mellitus: 0.2 units/kg SQ daily
- Transitioning from other agents
- Transitioning to other agents
VI. Adverse Effects
- See Insulin
VIII. References
- (2018) Presc Lett 25(8)
- Riddle (2014) Diabetes Care 37(10):2755-62 +PMID:25078900 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
toujeo (on 4/20/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
TOUJEO MAX SOLOSTR 300 UNIT/ML | $82.96 per ml | |
TOUJEO SOLOSTAR 300 UNIT/ML | $82.93 per ml |